Related Experiment Video
Updated: Feb 4, 2026

Author Spotlight: Deciphering the Role of ATM in Ataxia-Telangiectasia and the Associated Cerebellar Degeneration
Published on: December 27, 2024
DNA damage sensitivity of SWI/SNF-deficient cells depends on TFIIH subunit p62/GTF2H1
Cristina Ribeiro-Silva1, Özge Z Aydin1,2, Raquel Mesquita-Ribeiro3
1Department of Molecular Genetics, Oncode Institute, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Abstract:
Mutations in SWI/SNF genes are amongst the most common across all human cancers, but efficient therapeutic approaches that exploit vulnerabilities caused by SWI/SNF mutations are currently lacking. Here, we show that the SWI/SNF ATPases BRM/SMARCA2 and BRG1/SMARCA4 promote the expression of p62/GTF2H1, a core subunit of the transcription factor IIH (TFIIH) complex. Inactivation of either ATPase subunit downregulates GTF2H1 and therefore compromises TFIIH stability and function in transcription and nucleotide excision repair (NER). We also demonstrate that cells with permanent BRM or BRG1 depletion have the ability to restore GTF2H1 expression. As a consequence, the sensitivity of SWI/SNF-deficient cells to DNA damage induced by UV irradiation and cisplatin treatment depends on GTF2H1 levels. Together, our results expose GTF2H1 as a potential novel predictive marker of platinum drug sensitivity in SWI/SNF-deficient cancer cells.
Insights
SWI/SNF gene mutations are common in cancer. This study reveals GTF2H1 as a potential marker for predicting platinum drug sensitivity in SWI/SNF-deficient cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Mutations in SWI/SNF genes are prevalent in human cancers, yet targeted therapies remain limited.
- SWI/SNF ATPases, BRM/SMARCA2 and BRG1/SMARCA4, are crucial for cellular processes.
- Understanding SWI/SNF mutation-associated vulnerabilities is critical for developing new cancer treatments.
Purpose of the Study:
- To investigate the role of SWI/SNF ATPases in regulating GTF2H1 expression.
- To determine the impact of SWI/SNF inactivation on TFIIH complex stability and function.
- To identify potential therapeutic targets and predictive markers in SWI/SNF-mutated cancers.
Main Methods:
- Gene expression analysis to assess GTF2H1 levels following SWI/SNF ATPase inactivation.
- Assessment of TFIIH complex stability and its roles in transcription and nucleotide excision repair (NER).
- Evaluation of cellular sensitivity to DNA-damaging agents (UV irradiation, cisplatin) in SWI/SNF-deficient cells with varying GTF2H1 levels.
Main Results:
- SWI/SNF ATPases BRM/SMARCA2 and BRG1/SMARCA4 positively regulate p62/GTF2H1 expression.
- Inactivation of BRM or BRG1 leads to decreased GTF2H1 levels, compromising TFIIH function in transcription and NER.
- Cancer cells with SWI/SNF deficiencies can restore GTF2H1 expression, influencing their DNA damage sensitivity.
Conclusions:
- GTF2H1 is a key downstream target regulated by SWI/SNF ATPases.
- GTF2H1 levels are critical for the DNA repair capacity and drug sensitivity of SWI/SNF-mutated cancer cells.
- GTF2H1 emerges as a promising predictive biomarker for platinum-based chemotherapy response in SWI/SNF-deficient cancers.
Related Concept Videos
DNA Damage Can Stall the Cell Cycle
DNA Damage can Stall the Cell Cycle
Contact-dependent Signaling
Gap Junctions
In animal cells, gap junctions are formed...
Translesion DNA Polymerases
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
DNA Helicases
The DNA Helix

